Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 88 citing articles:

Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk
Alexander Blood, Lee‐Shing Chang, Caitlin Colling, et al.
Primary care diabetes (2024) Vol. 18, Iss. 2, pp. 202-209
Open Access | Times Cited: 4
The prevalence of cardiovascular diseases, chronic kidney disease, and obesity in patients with type 2 diabetes mellitus and the description of concurrent treatments: A two-center retrospective cross-sectional study in Saudi Arabia
Omar A. Alshaya, Ghazwa B. Korayem, Munirah Alghwainm, et al.
Saudi Pharmaceutical Journal (2024) Vol. 32, Iss. 5, pp. 102054-102054
Open Access | Times Cited: 4
Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
Chutintorn Sriphrapradang, Ammarin Thakkinstian, Ratiporn Chinthammit, et al.
Journal of Diabetes Investigation (2025)
Open Access
Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a Department of Veterans Affairs quality improvement intervention
Shira Yun, Kathryn M. Hurren, Rob Holleman, et al.
BMC Primary Care (2025) Vol. 26, Iss. 1
Open Access
Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure
Sara J. Cromer, Julie C. Lauffenburger, Raisa Levin, et al.
Diabetes Care (2022) Vol. 46, Iss. 1, pp. 65-74
Open Access | Times Cited: 18
Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample
Shichao Tang, Hui Shao, Mohammed K. Ali, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 582-583
Open Access | Times Cited: 9
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
Muhammad Shahzeb Khan, Matthew W. Segar, Muhammad Usman, et al.
JACC Heart Failure (2023) Vol. 11, Iss. 7, pp. 825-835
Open Access | Times Cited: 9
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 13, pp. 100184-100184
Open Access | Times Cited: 9
Using Behavioral Economics to Reduce Low-Value Care Among Older Adults
Jeffrey T. Kullgren, H. Myra Kim, Megan Slowey, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 3, pp. 281-281
Closed Access | Times Cited: 3
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation
André Scheen
The Lancet Regional Health - Europe (2023) Vol. 29, pp. 100627-100627
Open Access | Times Cited: 8
Pharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel
Beini Lyu, Yingying Sang, Elizabeth Selvin, et al.
Diabetes Care (2022) Vol. 45, Iss. 12, pp. 2926-2934
Open Access | Times Cited: 13
Is it time to repurpose geroprotective diabetes medications for prevention of dementia?
Diana He, Sandra Aleksić
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2041-2045
Open Access | Times Cited: 7
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
André Scheen
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 11, pp. 1053-1062
Closed Access | Times Cited: 7
Impact of Residential Social Deprivation on Prediction of Heart Failure in Patients With Type 2 Diabetes: External Validation and Recalibration of the WATCH-DM Score Using Real World Data
Salil V. Deo, Sadeer Al‐Kindi, Issam Motairek, et al.
Circulation Cardiovascular Quality and Outcomes (2024) Vol. 17, Iss. 3
Closed Access | Times Cited: 2
Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study
Lurit Bepo, Oanh Kieu Nguyen, Anil N. Makam
Journal of General Internal Medicine (2024) Vol. 39, Iss. 15, pp. 2987-2994
Open Access | Times Cited: 2
Population Health Management and Guideline-Concordant Care in CKD
Melanie R. Weltman, Linda-Marie Ustaris Lavenburg, Zhuoheng Han, et al.
Journal of the American Society of Nephrology (2024)
Open Access | Times Cited: 2
Early combination therapy with SGLT2i and GLP‐1 RA or dual GIP/GLP‐1 RA in type 2 diabetes
Catarina Vale, Inês Mariana Lourenço, Gabriela Jordan, et al.
Diabetes Obesity and Metabolism (2024) Vol. 27, Iss. 2, pp. 468-481
Closed Access | Times Cited: 2
SGLT2 inhibitors and finerenone: one or the other or both?
Brendon L. Neuen, Meg Jardine
Nephrology Dialysis Transplantation (2022) Vol. 37, Iss. 7, pp. 1209-1211
Open Access | Times Cited: 11
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Kevin Yau, Ayodele Odutayo, Satya Dash, et al.
Canadian Journal of Cardiology (2023) Vol. 39, Iss. 12, pp. 1816-1838
Closed Access | Times Cited: 6
Guideline-Concordant Statin Therapy Use in Secondary Prevention
Salim S. Virani, Christie M. Ballantyne, Laura A. Petersen
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 18, pp. 1814-1817
Open Access | Times Cited: 10
The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study
Ghazwa B. Korayem, Omar A. Alshaya, Albandari A. Alghamdi, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 10
Impact of American Diabetes Association 2022 Guidelines on Prescribing Rates of Sodium-Glucose Cotransporter-2 Inhibitors in Ambulatory Care Organization Patients With Type 2 Diabetes
Alexis R. Bogannam, Ewan D McNicol, Kevin DeLeonardo, et al.
Journal of Pharmacy Practice (2024) Vol. 37, Iss. 6, pp. 1267-1274
Closed Access | Times Cited: 1
Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
Francisco Simões de Carvalho, Francisca de Brito Marques, Ana Elisa Lopes, et al.
Cureus (2023)
Open Access | Times Cited: 4
Optimizing SGLT2 inhibitor and GLP-1 RA Prescribing in High-Risk Patients with Diabetes: A Department of Veterans Affairs Quality Improvement Intervention
Shira Yun, Kathryn M. Hurren, Rob Holleman, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1

Scroll to top